using neuroimaging, authors try to collect evidence associating polluting cooking fuels with cognitive function impairement in rural aging Indians.
The article provides a comprehensive overview of the role of the endogenous detoxification system in the pathogenesis of age-related neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). It highlights epidemiological evidence linking environmental toxicant exposure to the onset and progression of these diseases, and discusses how dysfunction of detoxification pathways, including enzymes and transporters, can exacerbate neurodegenerative processes. The article also explores the potential of targeting nuclear receptor signaling pathways, such as the pregnane X receptor (PXR), as a promising therapeutic strategy to restore detoxification capacity and modify disease trajectories.
Elsevier,

Journal of Prevention of Alzheimer's Disease, Volume 12, 1 August 2025

The study found that long-duration and high-intensity walking were associated with reduced amyloid-beta accumulation over 4 years, with the greatest benefits seen in those who started walking earlier in life. However, walking activity was not linked to changes in tau deposition, neurodegeneration, or white matter hyperintensities.
The article estimates the value-based price of a blood test for Alzheimer's disease pathology, finding it would be $290-$1150 in primary care and $450-$1950 in specialty care, projecting substantial cost savings.
Elsevier,

Journal of Pharmacology and Experimental Therapeutics, Volume 392, August 2025

This review discusses the dual role of amyloid-beta (Aβ) in Alzheimer's disease (AD). While Aβ accumulation is a hallmark of AD pathology, soluble Aβ also plays a neuroprotective role in regulating synaptic plasticity and memory. The review explores the potential of anti-Aβ immunotherapy as a treatment strategy, highlighting the need to balance targeting toxic Aβ species while preserving the physiological functions of Aβ.`
This article describes the discovery and characterization of FJMU1887, a novel brain-penetrant small-molecule inhibitor of Galectin-3 (Gal-3) identified through an AI-driven drug discovery platform. FJMU1887 demonstrated potent anti-inflammatory effects, reduced Aβ pathology, and improved cognitive function in Alzheimer's disease mouse models, highlighting its therapeutic potential for the treatment of Alzheimer's disease.
This study investigated how repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training affects functional connectivity in both gray matter and white matter in patients with mild to moderate Alzheimer’s disease. Results showed that rTMS modulated activity in key brain regions, particularly within the limbic system, with changes in white matter connectivity correlating with cognitive improvements.

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by considering the role heavy metals such as lead, mercury, and cadmium can play in Alzheimer's Disease.

Ceria nanoclusters, with their ultra-small particle size and and targeted peptides, provides substantial penetration of the blood drain barrier for rapid and susptained relief from neuroinflammation.

This study demonstrates that deep learning models, especially Graph Convolutional Networks can effectively and accurately differentiate healthy individuals from those with mild cognitive impairment and Alzheimer's disease, supporting early diagnosis of cognitive decline.

Pages